IP Verse

Ipsen Biopharm patent opposition analysis

Get complete Patent Opposition Report for Ipsen Biopharm

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Latest oppositions filed by Ipsen Biopharm

Explore patent oppositions filed by Ipsen Biopharm against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent Number	Title	Applicant	Opposition Date
EP3368071	Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect	REVANCE THERAPEUTICS	Oct 26, 2022
EP3094331	Combination-Based Treatment Method	NEKTAR THERAPEUTICS	Sep 27, 2018

Latest patents of Ipsen Biopharm opposed by its competitors

Explore Ipsen Biopharm's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent Number	Grant Date	Title	Total Oppositions
EP3266456	May 5, 2021	Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer	3
EP3337467	Dec 9, 2020	Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment	1
EP3337478	Aug 12, 2020	Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin	2
EP2939688	Feb 20, 2019	Pharmaceutical Compositions Comprising Botulinum Neurotoxin	1
EP2861210	May 3, 2017	Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan	1

Top competitors of Ipsen Biopharm

SANDOZ

GENERICS UK

TEVA PHARMACEUTICAL INDUSTRIES